Dermata Reports Positive Phase 3 Trial Results

Dermata Therapeutics ( (DRMA) ) just unveiled an update.

In the first quarter of 2025, Dermata Therapeutics announced positive results from its XYNGARI™ Phase 3 STAR-1 clinical trial for acne, achieving all co-primary endpoints, and entered a collaboration with Revance Therapeutics to study DMT410 with DAXXIFY® for axillary hyperhidrosis. The company raised $8.8 million in gross proceeds, which will fund operations into early 2026, and reported decreased research and administrative expenses compared to the previous year.

The most recent analyst rating on (DRMA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Dermata Therapeutics stock, see the DRMA Stock Forecast page.

Spark’s Take on DRMA Stock

According to Spark, TipRanks’ AI Analyst, DRMA is a Underperform.

Dermata Therapeutics’ stock is primarily impacted by its financial health, characterized by significant operating losses and reliance on external financing. Technical analysis indicates a bearish trend with potential overselling, while valuation remains difficult to assess due to negative earnings. These factors contribute to a low overall score.

To see Spark’s full report on DRMA stock, click here.

More about Dermata Therapeutics

Dermata Therapeutics is a late-stage biotechnology company based in San Diego, California, focusing on the treatment of medical skin diseases and aesthetic applications. Its lead product candidate, XYNGARI™, is a once-weekly, topical treatment derived from a naturally sourced freshwater sponge, targeting conditions such as acne, psoriasis, and rosacea. The company also develops DMT410 for needle-free intradermal delivery of botulinum toxin for various skin conditions.

Average Trading Volume: 1,542,406

Technical Sentiment Signal: Sell

Current Market Cap: $4.79M

Learn more about DRMA stock on TipRanks’ Stock Analysis page.